Evidence map›Paper›PMID 31903162›Full record

ArticleOncotarget2019

Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer.

Anna S Gerdtsson, Jana-Aletta Thiele, Stephanie N Shishido, Serena Zheng, Randolph Schaffer, Kelly Bethel, Steven Curley, Heinz-Josef Lenz, Diana L Hanna, Jorge Nieva and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Anna S GerdtssonUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Jana-Aletta ThieleBiomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Stephanie N ShishidoUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Serena ZhengUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Randolph SchafferScripps MDAnderson Cancer Center, La Jolla, CA, USA.
Kelly BethelScripps MDAnderson Cancer Center, La Jolla, CA, USA.
Steven CurleyDivision of Surgical Oncology, Baylor College of Medicine, Houston, TX, USA.
Heinz-Josef LenzKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Diana L HannaKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Jorge NievaKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Anand KolatkarUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Carmen RuizUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Mariam Rodriguez-LeeUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Gerard J Oakley IiiDiagnostic and Experimental Pathology, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Jerry S H LeeKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.
James HicksUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Peter KuhnUSC Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
Convergent Science (United States) · USUniversity of Southern California · USScripps MD Anderson Cancer Center · USBaylor College of Medicine · USCharles University · CZEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As cancer care is transitioning to personalized therapies with necessary complementary or companion biomarkers there is significant interest in determining to what extent non-invasive liquid biopsies reflect the gold standard solid biopsy. We have established an approach for measuring patient-specific circulating and solid cell concordance by introducing tumor touch preparations to the High-Definition Single Cell Analysis workflow for high-resolution cytomorphometric characterization of metastatic colorectal cancer (mCRC). Subgroups of cells based on size, shape and protein expression were identified in both liquid and solid biopsies, which overall displayed high inter- and intra- patient pleomorphism at the single-cell level of analysis. Concordance of liquid and solid biopsies was patient-dependent and between 0.1-0.9. Morphometric variables displayed particularly high correlation, suggesting that circulating cells do not represent distinct subpopulations from the solid tumor. This was further substantiated by significant decrease in concentration of circulating cells after mCRC resection. Combined with the association of circulating cells with tumor burden and necrosis of hepatic lesions, our overall findings demonstrate that liquid biopsy cells can be informative biomarkers in the mCRC setting. Patient-specific level of concordance can readily be measured to establish the utility of circulating cells as biomarkers and define biosignatures for liquid biopsy assays.

Indexed as

circulating tumor cellscytomorphologyliquid biopsymetastatic colorectal cancersingle cell analysis

Identifiers

PMID31903162
PMCPMC6925029
OpenAlexW2998465792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.